HHS Requests Testosterone Label Updates After TRAVERSE Trial

Originally surfaced June 24, 2026, drawing on a June 18 HHS announcement about FDA-requested testosterone therapy label updates and FDA's earlier class-wide testosterone labeling action after TRAVERSE.

The testosterone label story is easy to overstate, so the timeline matters.

On June 18, HHS announced that FDA is requesting updates to prescribing information for testosterone replacement therapy products after reviewing new clinical data and existing evidence. The requested updates include removing the limitation-of-use language saying safety and effectiveness have not been established for men with age-related hypogonadism, updating prostate cancer language, and revising benign prostatic hyperplasia warnings.

That June 18 HHS announcement builds on an earlier FDA action from February 28, 2025. In that class-wide labeling update, FDA said it was removing boxed-warning language related to increased risk of adverse cardiovascular outcomes for all testosterone products, adding TRAVERSE trial results to all testosterone products, retaining the limitation-of-use language for age-related hypogonadism at that time, and adding blood-pressure warning language based on ambulatory blood pressure monitoring studies.

The distinction is not pedantic. The cardiovascular boxed-warning change is already part of FDA's February 2025 testosterone label action. The June 2026 news hook is broader: HHS now says FDA is requesting additional label updates around the age-related limitation, prostate cancer, and BPH language.

What TRAVERSE actually showed

The key trial behind the cardiovascular rethink was TRAVERSE, published in the New England Journal of Medicine in July 2023. The study enrolled 5,246 men with hypogonadism who had either established cardiovascular disease or a high risk of developing it. Participants were randomized to transdermal testosterone or placebo and followed for a mean treatment duration of about 22 months and mean follow-up of about 33 months.

Major adverse cardiovascular events occurred in 7.0% of the testosterone group and 7.3% of the placebo group. The hazard ratio was 0.96, and the trial met its prespecified noninferiority threshold.

That is meaningful. It is also narrower than saying testosterone is cardiovascular-safe for everyone. TRAVERSE tested a defined group of men with hypogonadism and substantial cardiovascular risk. It did not show that testosterone reduces cardiovascular risk, and it did not erase every safety signal. The NEJM publication reported higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group.

What changed for the label discussion

FDA's February 2025 label action turned the cardiovascular language from a broad warning into something more specific. The agency said TRAVERSE found no increase in adverse cardiovascular outcomes in men using testosterone for hypogonadism, while ambulatory blood pressure monitoring studies confirmed increased blood pressure with testosterone products as a class.

That creates a more useful risk frame. The old warning implied a blunt cardiovascular-harm concern. The newer label direction keeps cardiovascular monitoring in the conversation, but shifts attention toward product-specific blood pressure information and other observed risks.

The June 2026 HHS announcement goes further by saying FDA is requesting updates to the age-related hypogonadism limitation, prostate cancer language, and BPH warnings. HHS says FDA has concluded the age-related limitation is no longer warranted after reviewing TRAVERSE and other evidence. It also says the requested prostate cancer language would contraindicate testosterone therapy only in men with metastatic prostate cancer, while still recommending risk assessment, screening, and monitoring.

Where testing fits

For people evaluating low testosterone symptoms, the starting point is still measurement, not a label headline. A testosterone blood test can establish whether total testosterone is low on a blood draw. A free and total testosterone test may add context in some situations, and a broader men's health panel can put testosterone beside other markers.

That baseline role does not change because HHS requested label revisions. Lab results do not diagnose hypogonadism by themselves, decide whether testosterone therapy is appropriate, or settle prostate or cardiovascular risk. They give a concrete number for a clinician conversation that otherwise tends to drift into symptoms, age, marketing, and anxiety.

What not to overread

This is not a recommendation to start, stop, or change testosterone therapy. It is not a claim that testosterone therapy is risk-free. It is also not a claim that every man with fatigue, low libido, or low mood needs testosterone testing.

The clean takeaway is narrower: FDA's cardiovascular label posture has moved away from a broad boxed-warning concern after TRAVERSE, while HHS now says FDA is requesting additional label updates on age-related hypogonadism, prostate cancer, and BPH language. The lab-testing angle is simple: if low testosterone is part of the question, measuring testosterone is the evidence step before any treatment discussion.

This article is editorial commentary and is not medical advice. It has not been reviewed by a physician and should not be used to make decisions about diagnosis, testosterone therapy, prostate screening, cardiovascular care, blood pressure management, medication use, or testing frequency.